BD (NYSE:BDX) announced today that it launched its Neopak XtraFlow glass prefillable syringe and expanded the capacity for the platform. The company said the launch and expansion aim to serve the growing market for biologic therapies. Neopak glass prefillable syringes address key development needs for biologic drugs, BD said in a news release. The syringes […]
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]
Sirtex Medical begins European launch for microsphere delivery system following EU approval
Sirtex Medical announced today that it received EU MDR certification to market its SIR-Spheres Y-90 resin microspheres and delivery systems. EU MDR authorization enables Woburn, Massachusetts-based Sirtex to kick off a European launch for its Siros delivery system. Siros offers an intuitive, visual and adaptable solution for physicians to administer SIR-Spheres to liver cancer patients. […]
Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as […]
Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to […]
NanoSyrinx raises $13M to support nanosyringe tech
NanoSyrinx, a synthetic biology company developing nanosyringes, announced that it closed a £10 million ($13 million) financing round. BGF, Octopus Ventures and M Ventures led the financing. Existing investors IQ Capital and Meltwind also participated. According to a news release, pharmaceutical giant Eli Lilly took part in the funding round as well. NanoSyrinx also named […]
Orange Biomed to showcase microfluidic-based A1C test
Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting. The company intends to present research for the device during the event’s Startup Showcase next month. It developed the pocket-sized, single-cell, micro-electro-mechanical A1C analysis device, agnostic to hemoglobin variants, to deliver faster, more reliable results for […]
CorFlow Therapeutics raises $48.5M for diagnostic, drug delivery platform
CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes Partners led the financing round. 415 Capital, Merieux Equity Partners, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital also participated. […]
Dexcom CGM worn in outer space on Polaris Dawn mission
Dexcom (Nasdaq:DXCM) announced today that its G6 CGM is being worn by astronauts as part of the Polaris Dawn mission. Polaris Dawn launched this morning with astronauts wearing the G6 to better understand the effects of spaceflight on human health. The crew intends to conduct research to advance human health on Earth and the understanding […]
CSA Medical raises $53M to support metered cryospray tech
CSA Medical announced today that it completed an oversubscribed Series D preferred stock equity financing worth $53 million. TVM Capital Life Science and Yonjin Ventures co-led the funding round. Existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron and Intersouth Partners also participated. In connection with the financing, Dr. Luc Marengere of TVM […]
